Viemed Healthcare, Inc 10-Q for FY2026 Q3
Viemed Healthcare, Inc. (VMD)
10-Q
2026-11-04
For: 2026-09-30
View Original
Added on
November 04, 2026
About this 10-Q
Viemed Healthcare, Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $80.67M
- up 12.2% from $71.91M a year earlier
- Net income
- $4.64M
- up 32.0% from net income of $3.51M a year earlier
- Diluted EPS
- $0.11
- up 22.2% from $0.09 a year earlier
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the quarterly period ended September 30, 2026
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the transition period from _____ to _____
Commission file number: 001-38973
(Exact name of registrant as specified in its charter)
British Columbia, | N/A | |||||||
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification Number) | |||||||
| (Address of principal executive offices, including zip code) | ||||||||
( | ||||||||
| (Registrant’s telephone number, including area code) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Non-Accelerated filer ☐ | Smaller reporting company Emerging growth company | ||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
As of October 27, 2026, there were 37,893,094 common shares of the registrant outstanding.
VIEMED HEALTHCARE, INC. TABLE OF CONTENTS | ||||||||
September 30, 2026 and 2025 | ||||||||
| Page | ||||||||
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
| VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||||||||
| (Expressed in thousands of U.S. Dollars, except outstanding shares) | |||||||||||||||||
| Note | At September 30, 2026 | At December 31, 2025 | |||||||||||||||
| (Unaudited) | (Audited) | ||||||||||||||||
| ASSETS | |||||||||||||||||
| Current assets | |||||||||||||||||
| Cash and cash equivalents | 2 | $ | $ | ||||||||||||||
| Accounts receivable, net | 2 | ||||||||||||||||
| Inventory | 2 | ||||||||||||||||
| Income tax receivable | |||||||||||||||||
| Prepaid expenses and other assets | |||||||||||||||||
| Total current assets | $ | $ | |||||||||||||||
| Long-term assets | |||||||||||||||||
| Property and equipment, net | 3 | ||||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||||
| Equity investments | 2 | ||||||||||||||||
| Deferred tax asset | 9 | ||||||||||||||||
| Identifiable intangibles, net | 2 | ||||||||||||||||
| Goodwill | |||||||||||||||||
| Total long-term assets | $ | $ | |||||||||||||||
| TOTAL ASSETS | $ | $ | |||||||||||||||
| LIABILITIES | |||||||||||||||||
| Current liabilities | |||||||||||||||||
| Trade payables | $ | $ | |||||||||||||||
| Deferred revenue | |||||||||||||||||
| Income taxes payable | |||||||||||||||||
| Accrued liabilities | 4 | ||||||||||||||||
| Operating lease liabilities, current portion | 5 | ||||||||||||||||
Current portion of long-term debt | 5 | ||||||||||||||||
| Total current liabilities | $ | $ | |||||||||||||||
| Long-term liabilities | |||||||||||||||||
| Accrued liabilities | 7 | ||||||||||||||||
| Operating lease liabilities, less current portion | 5 | ||||||||||||||||
| Long-term debt | 5 | ||||||||||||||||
| Total long-term liabilities | $ | $ | |||||||||||||||
| TOTAL LIABILITIES | $ | $ | |||||||||||||||
| Commitments and Contingencies | |||||||||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||||||||
Common stock - No par value: unlimited authorized; | 7 | $ | $ | ||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Retained earnings | |||||||||||||||||
TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY | $ | $ | |||||||||||||||
Noncontrolling interest in subsidiary | |||||||||||||||||
TOTAL SHAREHOLDERS' EQUITY | |||||||||||||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | $ | |||||||||||||||
| See accompanying notes to the condensed consolidated financial statements | ||||||||
Page 3 | ||||||||
VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME | ||
(Expressed in thousands of U.S. Dollars, except share and per share amounts) (Unaudited) | ||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||
| Note | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||||
| Revenue | 2 | $ | $ | $ | $ | ||||||||||||||||||||||||
| Cost of revenue | |||||||||||||||||||||||||||||
| Gross profit | $ | $ | $ | $ | |||||||||||||||||||||||||
| Operating expenses | |||||||||||||||||||||||||||||
| Selling, general and administrative | |||||||||||||||||||||||||||||
| Research and development | |||||||||||||||||||||||||||||
| Stock-based compensation | 7 | ||||||||||||||||||||||||||||
Depreciation and amortization | |||||||||||||||||||||||||||||
| Loss (gain) on disposal of property and equipment | ( | ||||||||||||||||||||||||||||
| Other income, net | ( | ( | ( | ( | |||||||||||||||||||||||||
| Income from operations | $ | $ | $ | $ | |||||||||||||||||||||||||
| Non-operating income and expenses | |||||||||||||||||||||||||||||
| Loss from investments | |||||||||||||||||||||||||||||
Interest expense, net | 5 | ||||||||||||||||||||||||||||
| Net income before taxes | |||||||||||||||||||||||||||||
| Provision for income taxes | 9 | ||||||||||||||||||||||||||||
| Net income | $ | $ | $ | $ | |||||||||||||||||||||||||
| Net income attributable to noncontrolling interest | |||||||||||||||||||||||||||||
| Net income attributable to Viemed Healthcare, Inc. | $ | $ | $ | $ | |||||||||||||||||||||||||
| Net income per share | |||||||||||||||||||||||||||||
| Basic | 10 | $ | $ | $ | $ | ||||||||||||||||||||||||
| Diluted | 10 | $ | $ | $ | $ | ||||||||||||||||||||||||
| Weighted average number of common shares outstanding: | |||||||||||||||||||||||||||||
| Basic | 10 | ||||||||||||||||||||||||||||
| Diluted | 10 | ||||||||||||||||||||||||||||
See accompanying notes to the condensed consolidated financial statements | ||||||||||||||
Page 4 | ||||||||||||||
VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY | ||||||||
| (Expressed in thousands of U.S. Dollars, except share and per share amounts) (Unaudited) | ||||||||
| Common Stock | Additional paid-in capital | Noncontrolling interest in subsidiary | Total Shareholders' equity | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Retained earnings | |||||||||||||||||||||||||||||||||||||||
| Shareholders' equity, December 31, 2024 | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation - options | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Stock-based compensation - restricted stock | — | — | — | — | |||||||||||||||||||||||||||||||||||||
| Exercise of options | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Shares issued for vesting of restricted stock units | ( | — | — | ||||||||||||||||||||||||||||||||||||||
| Shares redeemed to pay income tax | ( | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||
| Net income | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Shareholders' equity, March 31, 2025 | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation - options | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Stock-based compensation - restricted stock | — | — | — | — | |||||||||||||||||||||||||||||||||||||
| Exercise of options | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Shares issued for vesting of restricted stock units | ( | — | — | ||||||||||||||||||||||||||||||||||||||
Shares redeemed to pay income tax | ( | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||
| Distribution to non-controlling interest | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||
| Share repurchases | ( | ( | — | — | ( | ||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Shareholders' equity, June 30, 2025 | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation - options | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Stock-based compensation - restricted stock | — | — | — | — | |||||||||||||||||||||||||||||||||||||
| Exercise of options | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Shares issued for vesting of restricted stock units | ( | — | — | — | |||||||||||||||||||||||||||||||||||||
Shares redeemed to pay income tax | ( | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||
| Distribution to non-controlling interest | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||
| Share repurchases | ( | ( | — | — | ( | ||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | ||||||||||||||||||||||||||||||||||||||
Shareholders' equity, September 30, 2025 | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||
See accompanying notes to the condensed consolidated financial statements | ||||||||||||||
Page 5 | ||||||||||||||
VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY | ||||||||
| (Expressed in thousands of U.S. Dollars, except share and per share amounts) (Unaudited) | ||||||||
| Common Stock | Additional paid-in capital | Noncontrolling interest in subsidiary | Total Shareholders' equity | |||||||||||||||||||||||||||||||||||
| Shares | Amount | Retained earnings | ||||||||||||||||||||||||||||||||||||
| Shareholders' equity, December 31, 2025 | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||
Stock-based compensation - restricted stock | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Exercise of options | — | — | — | |||||||||||||||||||||||||||||||||||
| Shares issued for vesting of restricted stock units | ( | — | — | |||||||||||||||||||||||||||||||||||
| Shares redeemed to pay income tax | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||
| Distribution to non-controlling interest | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
| Share repurchases | ( | ( | ( | — | — | ( | ||||||||||||||||||||||||||||||||
| Net income | — | — | — | |||||||||||||||||||||||||||||||||||
| Shareholders' equity, March 31, 2026 | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||
Stock-based compensation - restricted stock | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Exercise of options | — | — | — | |||||||||||||||||||||||||||||||||||
| Shares issued for vesting of restricted stock units | ( | — | — | |||||||||||||||||||||||||||||||||||
| Shares redeemed to pay income tax | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||
| Distribution to non-controlling interest | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
Share repurchases | ( | ( | ( | — | — | ( | ||||||||||||||||||||||||||||||||
| Net income | — | — | — | |||||||||||||||||||||||||||||||||||
| Shareholders' equity, June 30, 2026 | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||
Stock-based compensation - restricted stock | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Exercise of options | — | — | — | |||||||||||||||||||||||||||||||||||
| Shares issued for vesting of restricted stock units | ( | — | — | |||||||||||||||||||||||||||||||||||
| Shares redeemed to pay income tax | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||
| Distribution to non-controlling interest | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
Share repurchases | ( | ( | ( | — | — | ( | ||||||||||||||||||||||||||||||||
| Net income | — | — | — | |||||||||||||||||||||||||||||||||||
Shareholders' equity, September 30, 2026 | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||
See accompanying notes to the condensed consolidated financial statements | ||||||||||||||
Page 6 | ||||||||||||||
| VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||
(Expressed in thousands of U.S. Dollars) (Unaudited) | ||
| Nine Months Ended September 30, | |||||||||||||||||
| Note | 2026 | 2025 | |||||||||||||||
| Cash flows from operating activities | |||||||||||||||||
| Net income | $ | $ | |||||||||||||||
| Adjustments for: | |||||||||||||||||
Depreciation and amortization | |||||||||||||||||
| Stock-based compensation expense | 7 | ||||||||||||||||
| Loss (gain) on disposal of property and equipment | ( | ||||||||||||||||
Amortization of deferred financing costs | |||||||||||||||||
Deferred income tax expense | |||||||||||||||||
| Loss from other investments | |||||||||||||||||
Changes in working capital: | |||||||||||||||||
| Accounts receivable, net | ( | ( | |||||||||||||||
| Inventory | ( | ||||||||||||||||
| Prepaid expenses and other assets | ( | ( | |||||||||||||||
| Trade payables | |||||||||||||||||
| Deferred revenue | |||||||||||||||||
| Accrued liabilities | |||||||||||||||||
| Income tax payable/receivable | ( | ||||||||||||||||
| Net cash provided by operating activities | $ | $ | |||||||||||||||
| Cash flows from investing activities | |||||||||||||||||
| Purchase of property and equipment | 3 | ( | ( | ||||||||||||||
| Investment in equity investments | ( | ||||||||||||||||
Cash paid for acquisitions, net of cash acquired | ( | ||||||||||||||||
| Proceeds from sale of property and equipment | 3 | ||||||||||||||||
| Net cash used in investing activities | $ | ( | $ | ( | |||||||||||||
| Cash flows from financing activities | |||||||||||||||||
| Proceeds from exercise of options | 7 | ||||||||||||||||
Proceeds from term notes | |||||||||||||||||
| Principal payments on term notes | 5 | ( | ( | ||||||||||||||
Proceeds from revolving credit facilities | |||||||||||||||||
Payments on revolving credit facilities | ( | ||||||||||||||||
| Shares redeemed to pay income tax | 7 | ( | ( | ||||||||||||||
| Payments for share repurchase programs | 7 | ( | ( | ||||||||||||||
Repayments of finance lease liabilities | ( | ||||||||||||||||
Distributions to non-controlling interest | ( | ( | |||||||||||||||
Payments of acquisition-related contingent consideration | 6 | ( | |||||||||||||||
Net cash provided by (used in) financing activities | $ | ( | $ | ||||||||||||||
Net decrease in cash and cash equivalents | ( | ( | |||||||||||||||
| Cash and cash equivalents at beginning of year | |||||||||||||||||
| Cash and cash equivalents at end of period | $ | $ | |||||||||||||||
| Supplemental disclosures of cash flow information | |||||||||||||||||
| Cash paid during the period for interest | $ | $ | |||||||||||||||
Cash paid during the period for income taxes, net of refunds | $ | $ | |||||||||||||||
| Supplemental disclosures of non-cash transactions | |||||||||||||||||
Equipment and other fixed asset purchases payable at end of period | $ | $ | |||||||||||||||
| See accompanying notes to the condensed consolidated financial statements | ||||||||
Page 7 | ||||||||
| VIEMED HEALTHCARE, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | ||
| (Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts) (Unaudited) | ||
1. Nature of Business and Operations
Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute respiratory healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. The Company’s primary service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The Company serves patients in all 50 states of the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.
The Company’s common shares are traded on the Nasdaq Stock Market LLC under the symbol "VMD".
2. Summary of Significant Accounting Policies
Principles of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company's Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. The Company's fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2025 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the reports of the Company's independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.
As of December 31, 2024, the Company no longer qualified as an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, and is therefore no longer eligible for the related scaled disclosure and other reporting accommodations, including the exemption from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act.
Reporting Currency
All values are in U.S. dollars ($ or "USD"). Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts.
Basis of Consolidation
Use of Estimates
Page 8 | ||||||||
Segment Reporting
The Company’s chief operating decision-makers ("CODMs") are its Chief Executive Officer and Chief Operating Officer, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. The CODMs’ primary measure of segment profit or loss is consolidated net income, as presented on the Condensed Consolidated Statements of Income. The CODMs use this measure, together with other consolidated financial information, to assess performance trends, compare actual results to budgets and prior periods, and to allocate resources, including decisions related to personnel, operating infrastructure, capital expenditures, and acquisitions. In making these decisions, the CODMs review the Company’s results on a consolidated basis and do not evaluate operating results at a lower level.
There are no segment managers who are held accountable by the CODMs, or anyone else, for any planning, strategy, and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure. The CODMs do not receive or use additional disaggregated expense information beyond the expense categories presented on the Condensed Consolidated Statements of Income for purposes of resource allocation or performance assessment. As a result, all expense categories on the Condensed Consolidated Statements of Income are significant, and there are no other significant segment expenses that require disclosure.
The measure of segment assets is total consolidated assets, including goodwill, as presented on the Condensed Consolidated Balance Sheets. Assets provided to the CODMs are consistent with those reported on the Condensed Consolidated Balance Sheets, with particular emphasis on the Company’s available liquidity, including cash and cash equivalents. The CODMs do not receive information regarding assets at a lower level, and there are no other significant segment assets that require disclosure.
Accounts Receivable
Accounts receivable and revenues are based on contractually agreed-upon rates for services provided, reduced by estimated adjustments. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of adjustments, including variable consideration for implicit price concessions related to sales revenues and an estimate for probable losses related to net rental revenues. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws and regulations governing Medicare and Medicaid may result in adjustments to amounts originally recorded.
The Company performs a periodic analysis to review the valuation of accounts receivable and collectability of outstanding balances. These estimates are determined utilizing historical realization data under a portfolio approach, which is then assessed by management to evaluate whether adjustments should be made based on accounts receivable aging trends, other operating trends, and relevant business conditions such as governmental and managed care payor claims processing procedures.
The Company records a reserve for estimated probable losses as part of rental revenue adjustments in order to report rental revenue at an expected collectable amount based on the total portfolio of operating lease receivables for which collectability has been deemed probable.
Included in accounts receivable at September 30, 2026 are amounts due from Medicare representing 25 % of total outstanding net receivables. As of December 31, 2025, 25 % of total outstanding net receivables were amounts due from Medicare.
Inventory
Page 9 | ||||||||
Property and Equipment
Property and equipment, including capitalized internal-use software, is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized, while maintenance and repairs are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets.
Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient or placed in use. Depreciation of capitalized internal-use software commences when the software is ready for its intended use. Property and equipment with finite useful lives are evaluated for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable.
Equity Investments
Intangible Assets
Intangible assets include trade names and other identifiable intangible assets. Amortization expense related to definite lived identifiable intangible assets is included in depreciation and amortization in the accompanying Condensed Consolidated Statements of Income.
Revenue Recognition
Revenues are principally derived from the rental and sale of HME products and services to patients.
Rental revenues
Revenue generated from equipment that is rented to patients is recognized over the non-cancellable rental period (typically one month) and commences on delivery of the equipment to the patients. The agreements are evaluated at commencement and the start of each monthly renewal period to determine if it is reasonably certain that the monthly renewal or purchase options would be exercised. The exercise of monthly renewal or purchase options by a patient has historically not been reasonably certain to occur at lease commencement or subsequent monthly renewals.
Revenues are recorded at amounts estimated to be received under reimbursement arrangements with payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. Rental revenue, less estimated adjustments, is recognized as earned on a straight-line basis over the non-cancellable lease term. Rental of patient equipment is billed on a monthly basis beginning on the date the equipment is delivered. Since deliveries can occur on any day during a month, the amount of billings that apply to the next month are deferred.
The Company's lease agreements generally contain lease components and non-lease components, which primarily relate to supplies. The Company has made the accounting policy election to account for a lease component of an agreement and its associated non-lease components as a single lease component based on the Company's assessment of classification of the lease based on the consideration in the contract for the combined component.
Sales and Services revenues
Revenue related to sales of equipment and supplies is recognized on the date of delivery as this is when control of the promised goods is transferred to patients and is presented net of applicable sales taxes. Revenues are recorded only to the extent it is probable that a significant reversal will not occur in the future as amounts may include implicit price concessions under reimbursement arrangements with payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. The
Page 10 | ||||||||
sales transaction price is determined based on contractually agreed-upon rates, adjusted for estimates of variable consideration. The expected value method is used in determining the variable consideration as part of determining the sales transaction price using historical reimbursement experience, historical sales returns, and other operating trends. Payment terms and conditions vary by contract. The timing of revenue recognition, billing, and cash collection generally results in billed and unbilled accounts receivable.
The revenues from each major source are summarized in the following table:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
Revenue from rentals | ||||||||||||||||||||||||||
| Ventilator rentals, non-invasive and invasive | $ | $ | $ | $ | ||||||||||||||||||||||
Other home medical equipment rentals | ||||||||||||||||||||||||||
Revenue from sales and services | ||||||||||||||||||||||||||
Equipment and supply sales | ||||||||||||||||||||||||||
Service revenues | ||||||||||||||||||||||||||
| Total revenues | $ | $ | $ | $ | ||||||||||||||||||||||
Revenues from Medicare as a percentage of the Company's total revenue for the nine months ended September 30, 2026 and 2025 were 35 % and 39 %, respectively.
Stock-Based Compensation
The Company accounts for its stock-based compensation in accordance with ASC 718, "Compensation—Stock Compensation", which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award.
For the Company’s phantom share units ("PSUs") settled in cash, the Company computes the fair value of the PSUs using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.
Income Taxes
The Company is subject to income taxes in numerous U.S. jurisdictions. The Company's income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company's effective tax rate as well as the Company's business and operations.
Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future
Page 11 | ||||||||
operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.
Deferred tax is recognized on any temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable earnings. The effect of a change in the enacted tax rates is recognized in net earnings and comprehensive income or in equity depending on the item to which the adjustment relates. At each reporting period end, deferred tax assets are evaluated for recoverability based on whether it is more likely than not that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.
Business Combinations
The Company applies the acquisition method of accounting for business acquisitions. The results of operations of the business acquired by the Company are included as of the respective acquisition date. The acquisition-date fair value of the consideration transferred, including the fair value of any contingent consideration, is allocated to the underlying assets acquired, liabilities assumed, and noncontrolling interest in the acquiree based upon their estimated fair values at the date of acquisition. To the extent the acquisition-date fair value of the consideration transferred exceeds the fair value of the identifiable tangible and intangible assets acquired, liabilities assumed, and any noncontrolling interests, such excess is allocated to goodwill. Patient relationships, medical records and patient lists are not reported as separate intangible assets due to the regulatory requirements and lack of contractual agreements but are part of goodwill. Customer related relationships are not reported as separate intangible assets but are part of goodwill as authorizing physicians are under no obligation to refer the Company’s services to their patients, who are free to change physicians and service providers at any time. The Company may adjust the preliminary purchase price allocation, as necessary, as it obtains more information regarding asset valuations and liabilities assumed that existed but were not available at the acquisition date, which is generally up to one year after the acquisition closing date. Acquisition related costs are recognized separately from the business combination and are expensed as incurred.
Fair Value Measurements
Fair value is determined based on assumptions that a market participant would use in pricing an asset or liability. GAAP establishes a fair value hierarchy that prioritizes the inputs used in valuation techniques. Inputs are classified in Level 1 when valuation is based on quoted prices in active markets for identical assets or liabilities. Inputs are classified in Level 2 when valuation is based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable, market-corroborated inputs. Inputs are classified in Level 3 when valuation is based on significant unobservable inputs that reflect the assumptions the Company believes market participants would use in pricing the asset or liability.
The carrying amounts of cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued liabilities approximate fair value due to their short-term maturities. The carrying amounts outstanding under the Company’s credit facilities approximate fair value because the related interest rates are variable and reflective of current market rates. When estimated, the fair value of the Company’s debt is determined using observable market inputs and is classified within Level 2 of the fair value hierarchy.
Impairment of Goodwill and Long-Lived Assets
Goodwill resulting from business combinations is not amortized, rather, it is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects.
The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors, such as estimates of a reporting unit's fair value and judgment about impairment triggering events. As a result, there can be no assurance that the estimates and assumptions made for purposes of the annual or interim goodwill impairment test will prove to be accurate predictions of the future.
For the year ended December 31, 2025, the Company performed an assessment of qualitative factors and determined that no events or circumstances existed that would lead to a determination that it is more likely than not that the fair value of indefinite-lived
Page 12 | ||||||||
assets were less than the carrying amount. As such, a quantitative analysis was not required to be performed and the Company did not record any goodwill impairment charges.
The Company follows ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the asset group’s carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale, they are recorded at the lower of the carrying amount or the expected sales price less costs to sell. There were no
Net Income per Share Attributable to Viemed Healthcare, Inc.'s Common Stockholders
See Note 10 for earnings per share computations.
Recently Adopted Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid by jurisdiction. The ASU is effective for public business entities' annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard during the year ended December 31, 2025 on a retrospective basis.
Recently Issued Accounting Pronouncements
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (DISE), which specifies additional disclosure requirements. The new guidance requires additional disclosures, including the composition of certain income statement expense line items (such as purchases of inventory, employee compensation, and 'other expenses') and a separate disclosure for selling expenses. This change is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, however, early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.
In September 2025, the FASB issued ASU No. 2025-06, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40), which amends certain aspects of the accounting and disclosure requirements for internal-use software costs. The amendments remove references to software project development stages and provide updated guidance for assessing whether the probable-to-complete threshold for capitalization has been met. The ASU is effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual periods. Early adoption is permitted. The amendments may be applied prospectively, retrospectively, or using a modified prospective approach. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.
Page 13 | ||||||||
3. Property and Equipment
The Company’s fixed assets consist of its medical equipment held for rental, furniture and equipment, including capitalized internal-use software, real property and related improvements, and vehicles.
The following table details the Company’s fixed assets:
| September 30, 2026 | December 31, 2025 | |||||||||||||
| Medical equipment | $ | $ | ||||||||||||
| Furniture and equipment | ||||||||||||||
| Land | ||||||||||||||
| Buildings | ||||||||||||||
| Leasehold improvements | ||||||||||||||
| Vehicles | ||||||||||||||
| Less: Accumulated depreciation | ( | ( | ||||||||||||
Property and equipment, net of accumulated depreciation | $ | $ | ||||||||||||
4. Current Liabilities
The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:
| September 30, 2026 | December 31, 2025 | |||||||||||||
| Accrued trade payables | $ | $ | ||||||||||||
| Accrued commissions payable | ||||||||||||||
| Accrued bonuses payable | ||||||||||||||
| Accrued vacation and payroll | ||||||||||||||
| Current portion of phantom share liability | ||||||||||||||
| Acquisition-related contingent consideration | ||||||||||||||
| Accrued other liabilities | ||||||||||||||
| Total accrued liabilities | $ | $ | ||||||||||||
Supplier Financing Programs
The Company participates in supplier finance programs with third-party financial institutions in connection with the purchase of inventory and supplies. Under these arrangements, the Company's subsidiaries confirm invoices directly with a finance provider and agree to pay the finance provider the invoiced amount on the agreed payment date. The finance provider remits payment to the supplier upon the Company's confirmation of the invoice, effectively extending the Company's payment terms beyond standard supplier terms. The Company's obligations under these arrangements are non-cancelable and are structured with terms of up to 90 days, interest-free. The Company's payment obligations under these programs are not secured by collateral.
Obligations outstanding under these programs are included in trade payables in the Company’s Condensed Consolidated Balance Sheets. As of September 30, 2026, the Company had $0.9 million of obligations outstanding under these arrangements. There were no obligations outstanding under these arrangements as of December 31, 2025.
Page 14 | ||||||||
5. Debt and Lease Liabilities
Debt
The following table summarizes the Company’s debt as of September 30, 2026 and December 31, 2025:
| September 30, 2026 | December 31, 2025 | |||||||||||||
2022 Senior Credit Facilities | $ | $ | ||||||||||||
Financing costs and commitment fees | ( | ( | ||||||||||||
Current portion | ( | ( | ||||||||||||
Long-term portion | $ | $ | ||||||||||||
2022 Senior Credit Facilities
On November 29, 2022, the Company refinanced its existing borrowings under the 2018 Senior Credit Facility and entered into a new credit agreement (the "2022 Senior Credit Facilities") with the lenders from time to time party thereto, and Regions Bank, as administrative agent (the "Administrative Agent") and collateral agent, that provides for an up to $30.0 million revolving credit facility (the "2022 Revolving Credit Facility") and an up to $30.0 million delayed draw term loan facility (the "2022 Term Loan Facility"), both maturing in November 2027.
The proceeds of the 2022 Revolving Credit Facility may be used to refinance existing indebtedness, for working capital purposes, capital expenditures and other general corporate purposes (including permitted acquisitions), and to pay transaction fees, costs and expenses related to the 2022 Senior Credit Facilities. The proceeds of the 2022 Term Loan Facility and any additional term loans established in accordance with the 2022 Senior Credit Facilities may be used to finance permitted acquisitions and to pay transaction fees, costs and expenses related to such acquisitions.
The interest rates per annum applicable to the 2022 Senior Credit Facilities are a forward looking term rate based on a secured overnight financing rate ("Term SOFR") plus an applicable margin ranging from 2.625 % to 3.375 %, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625 % to 2.375 %.
The 2022 Senior Credit Facilities require the Company to comply with certain affirmative, as well as certain negative covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company to incur indebtedness, grant liens, make investments, engage in acquisitions, mergers or consolidations and pay dividends and other restricted payments. The 2022 Senior Credit Facilities also include certain financial covenants, which generally include, but are not limited to the following:
•Consolidated Total Leverage Ratio (defined generally as total indebtedness to adjusted EBITDA) of not greater than (i) for any fiscal quarter ending during the period from the closing date to and including December 31, 2024, 2.75 to 1.0 and (ii) for any fiscal quarter ending on and after March 31, 2025, 2.50 to 1.0, subject to certain adjustments following a material acquisition.
•Consolidated Fixed Charge Coverage Ratio (defined generally as (a) adjusted EBITDA minus capital expenditures minus cash taxes to (b) the sum of scheduled principal payments plus cash interest expense plus restricted payments) of not less than 1.25 :1.0.
The Company was in compliance with all covenants under the 2022 Senior Credit Facilities in effect at September 30, 2026.
The 2022 Senior Credit Facilities include provisions permitting the Company from time to time to, subject to certain terms and conditions, increase the aggregate amount of commitments under the 2022 Revolving Credit Facility and/or establish one or more additional term loans under the 2022 Term Loan Facility, in each case, with additional commitments from existing lenders or new commitments from financial institutions acceptable to the Administrative Agent in its reasonable discretion; provided, that, (a) the aggregate principal amount of any increases in the 2022 Revolving Credit Facility, and (b) the aggregate principal amount of all additional term loans under the 2022 Term Loan Facility established after the closing date will not exceed $30.0 million.
Page 15 | ||||||||
Financing costs related to the 2022 Senior Credit Facilities are capitalized and amortized over the term of the loans using the effective interest method. Upon the initial draw of debt under the 2022 Senior Credit Facilities during the year ended December 31, 2023, the Company reclassified the deferred financing fees previously recorded in other long-term assets to long-term debt in the Condensed Consolidated Balance Sheets.
On May 28, 2024, the Company entered into a First Amendment to the 2022 Senior Credit Facilities that (a) extended the delayed draw term loan commitment expiration date to November 29, 2025, from its initial expiration date of May 29, 2024, and (b) provided for other technical amendments. On June 6, 2025, the Company entered into a Second Amendment to the 2022 Senior Credit Facilities that (a) increased the permitted amount of restricted payments that may be made by the Company and its subsidiaries subject to specified conditions, and (b) made other conforming and administrative changes. On November 7, 2025, the Company entered into a Third Amendment to the 2022 Senior Credit Facilities that, among other things, (a) further extended the delayed draw term loan commitment expiration date from November 29, 2025 to November 29, 2026 and (b) included other technical amendments.
Leases
The Company has recognized operating leases for land and buildings that have terms greater than twelve months, as follows:
| September 30, 2026 | December 31, 2025 | |||||||||||||
| Lease liabilities | $ | $ | ||||||||||||
| Less: | ||||||||||||||
| Current portion of lease liabilities | ( | ( | ||||||||||||
| Net long-term lease liabilities | $ | $ | ||||||||||||
Operating Lease Liabilities
The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. The exercise of lease renewal options is at the Company's sole discretion and is included in the lease term for calculations of its right-of-use assets and liabilities when it is reasonably certain that the Company plans to renew these leases. These lease liabilities are recorded at their present value using a discount rate ranging from 5.5 % to 7.87 %, based on the Company's incremental borrowing rate at the time of assessment. At September 30, 2026, the weighted average lease term was approximately 3.29 years.
Future maturities of the Company's operating lease liabilities as of September 30, 2026 are summarized as follows:
| Lease Liability | ||||||||||||||
2026 (excluding the first nine months) | $ | |||||||||||||
| 2027 | ||||||||||||||
| 2028 | ||||||||||||||
| 2029 | ||||||||||||||
| 2030 | ||||||||||||||
| Thereafter | ||||||||||||||
| Total lease payments | $ | |||||||||||||
| Less: imputed interest | ||||||||||||||
| Present value of lease liabilities | $ | |||||||||||||
Page 16 | ||||||||
6. Fair Value Measurement
Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. There are three levels to the hierarchy based on the reliability of inputs, as follows:
Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.
Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company measures certain assets and liabilities at fair value on a recurring basis. There were no transfers between fair value measurement levels during any presented period. The following tables summarize the Company's assets and liabilities measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025:
| At September 30, 2026 | ||||||||||||||||||||||||||
| (In thousands) | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||
| Assets: | ||||||||||||||||||||||||||
| Money market mutual funds | $ | $ | $ | $ | ||||||||||||||||||||||
| At December 31, 2025 | ||||||||||||||||||||||||||
| (In thousands) | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||
Assets: | ||||||||||||||||||||||||||
| Money market mutual funds | $ | $ | $ | $ | ||||||||||||||||||||||
Liabilities: | ||||||||||||||||||||||||||
Acquisition-related contingent consideration | $ | $ | $ | $ | ||||||||||||||||||||||
Acquisition-Related Contingent Consideration
The Company estimated the fair value of acquisition-related contingent consideration liabilities using the income approach, based on a probability-weighted discounted cash flow model. Because this valuation relies on significant inputs that are not observable in active markets, it is classified as a Level 3 fair value measurement. Level 3 instruments are valued using unobservable inputs that reflect the assumptions the Company believes market participants would use in pricing the asset or liability. The Company reassesses the fair value of acquisition-related contingent consideration each reporting period, and any changes in estimated fair value are recognized in Other income, net in the Condensed Consolidated Statements of Income.
The contingent consideration liability was $1.8 no changes in the estimated fair value of the liability prior to settlement. As a result of the payment, there was no acquisition-related contingent consideration liability outstanding as of September 30, 2026.
Page 17 | ||||||||
Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
The Company measures certain assets and liabilities at fair value on a nonrecurring basis. These assets include other equity investments and the fair value allocation related to the Company’s acquisitions.
The Company's other equity investments are holdings in privately-held companies without a readily determinable market value. The Company remeasures equity securities without readily determinable fair value at fair value when an orderly transaction is identified for an identical or similar investment of the same issuer in accordance with the measurement alternative under Topic 820. ASU 2019-04 states that the measurement alternative is a nonrecurring fair value measurement. Accordingly, other equity investments without readily determinable fair value are classified within Level 3 in the fair value hierarchy because the Company estimates the value using a combination of observable and unobservable inputs, including valuation ascribed to the issuing company in subsequent financing rounds, volatility in the results of operations of the issuers and rights and obligations of the holdings the Company owns. The Company had no material adjustments of other equity investments measured at fair value on a nonrecurring basis during any of the periods presented.
The fair value allocation related to the Company’s acquisitions is determined using a discounted cash flow approach, or a replacement cost approach, which are based on significant unobservable inputs (Level 3). These valuation methods required management to make various assumptions, including, but not limited to, future profitability, cash flows, replacement costs, and discount rates. The Company’s estimates are based upon historical trends, management’s knowledge and experience and overall economic factors, including projections of future earnings potential. Developing discounted future cash flows in applying the income approach requires the Company to evaluate its intermediate to longer-term strategies, including, but not limited to, estimates of revenue growth, operating margins, capital requirements, inflation and working capital management. The development of appropriate rates to discount the estimated future cash flows requires the selection of risk premiums, which can materially impact the present value of future cash flows.
The Company estimated the fair value of acquired identifiable intangible assets using discounted cash flow techniques that included an estimate of future cash flows, consistent with overall cash flow projections used to determine the purchase price paid to acquire the business, discounted at a rate of return that reflects the relative risk of the cash flows. The Company estimated the fair value of certain acquired identifiable intangible assets based on the cost approach using estimated costs consistent with historical experience. The Company believes the estimates and assumptions used in the valuation methods are reasonable.
There were no transfers between fair value measurement levels during any presented period.
Page 18 | ||||||||
7. Shareholders' Equity
Authorized Share Capital
The Company’s authorized share capital consists of an unlimited number of common shares, with no stated par value.
Issued and Outstanding Share Capital
The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 38,053,094 38,019,082
During the nine months ended September 30, 2026, the Company repurchased and canceled 795,802 common shares at a cost of $7.5 million (excluding taxes) pursuant to the 2026 Share Repurchase Program and withheld and canceled 277,390 common shares with an aggregate value of $2.1 million to satisfy employee income tax withholding associated with RSUs vesting. The cost of shares repurchased and withheld is recorded as a reduction to shareholders’ equity.
Stock-Based Compensation
On June 6, 2024 (the "Effective Date"), the Company’s shareholders approved the Company's 2024 Long Term Incentive Plan (the "2024 Omnibus Plan") to provide an incentive to attract, retain, and reward directors, officers, employees, and consultants who provide services to the Company or any of its subsidiaries. All directors, officers, employees, and consultants of the Company and/or its affiliates are eligible to receive awards under the 2024 Omnibus Plan, subject to its terms. Awards include common share purchase options, restricted stock, stock appreciation rights, performance awards, or other stock-based awards, including restricted stock units, deferred stock units, and dividends and dividend equivalents.
On June 5, 2025, the Company's shareholders approved the first amendment to the 2024 Omnibus Plan, and on June 4, 2026, the Company's shareholders approved a second amendment (the "Second Amendment") to the 2024 Omnibus Plan. Following the Second Amendment, the maximum number of common shares that will be available for awards and issuance under the 2024 Omnibus Plan and that may be reserved for issuance at any time, including under previous plans such as the 2020 Long Term Incentive Plan (effective June 11, 2020), the Amended and Restated Stock Option Plan (effective as of July 17, 2018), the Amended and Restated Restricted Share Unit Plan (effective as of July 17, 2018), and the Deferred Share Unit Plan (effective July 17, 2018), is 7,696,717 shares. The maximum amount of common shares that may be awarded under the 2024 Omnibus Plan as “incentive stock options” is 1,000,000 common shares. As of September 30, 2026, the Company had outstanding options of 3,377,000 and RSUs of 2,449,000 associated with common shares under the existing plans.
The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2026 and 2025 (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Stock-based compensation - options | $ | $ | $ | $ | ||||||||||||||||||||||
| Stock-based compensation - restricted stock units | ||||||||||||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||||||||||||
At September 30, 2026, there was no remaining unrecognized pre-tax stock option expense under the Company's equity compensation plans. As of September 30, 2026, there was approximately $8.5 million of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 1.40 years.
Page 19 | ||||||||
Options
The following table summarizes stock option activity for the nine months ended September 30, 2026:
| Number of options (000's) | Weighted average exercise price(1) | Weighted average remaining contractual life | Aggregate intrinsic value(2) | |||||||||||||||||||||||
| Balance December 31, 2025 | $ | $ | ||||||||||||||||||||||||
| Issued | ||||||||||||||||||||||||||
| Exercised | ( | |||||||||||||||||||||||||
| Expired / Forfeited | ||||||||||||||||||||||||||
| Balance September 30, 2026 | $ | $ | ||||||||||||||||||||||||
(1)For presentation purposes, stock options issued with a Canadian dollar exercise price have been translated to U.S. dollars based on the prevailing exchange rate on the date of grant.
(2)The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing price of the Company's common shares on the last trading day of the period ($9.10 and $7.43 on September 30, 2026 and December 31, 2025, respectively).
The aggregate intrinsic value of options outstanding and options exercisable was $12.6 160,597 common shares were issued pursuant to the exercise of stock options.
At September 30, 2026, the Company had 3,377,000 exercisable stock options outstanding with a weighted average exercise price of $5.40 and a weighted average remaining contractual life of 3.4 years. At December 31, 2025, the Company had 3,538,000 exercisable stock options outstanding with a weighted average exercise price of $5.45 and a weighted average remaining contractual life of 4.1 years.
The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and credited to additional paid-in capital over the vesting period, using the grant date fair value based on the Black-Scholes option pricing model. The assumptions used to determine the grant date fair value of stock options include exercise price, risk-free interest rates, expected volatility, and average life of an option. The risk-free interest rates are based on the rates available at the time of the grant for zero-coupon U.S. government issues with a remaining term equal to the option’s expected life. The average life of an option is based on both historical and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on the Company's common shares and historical volatility of the Company's common shares over the expected life of the option. There were no issuances of options during the nine months ended September 30, 2026.
Restricted Stock Units
The Company accounts for RSUs using fair value. The fair value of the RSUs has been charged to the Condensed Consolidated Statements of Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant. RSUs vest generally over a or three-year period. The Company accounts for forfeitures of RSUs under ASU 2016-09 and recognizes forfeitures in the period in which they occur.
The following table summarizes RSU activity for the nine months ended September 30, 2026:
| Number of RSUs (000's) | Weighted average grant price | Weighted average remaining contractual life | Aggregate intrinsic value(1) | |||||||||||||||||||||||
| Balance December 31, 2025 | $ | $ | ||||||||||||||||||||||||
| Issued | ||||||||||||||||||||||||||
| Vested | ( | |||||||||||||||||||||||||
Forfeited | ( | |||||||||||||||||||||||||
| Balance September 30, 2026 | $ | $ | ||||||||||||||||||||||||
(1)The aggregate intrinsic value of time-based RSUs outstanding was based on the closing price of the Company's common shares on the last trading day of the period ($9.10 and $7.43 on September 30, 2026 and December 31, 2025, respectively).
During the nine months ended September 30, 2026, the Company issued 1,352,154 RSUs with a vesting term of or three years and a weighted-average fair value of $7.52 per share.
Page 20 | ||||||||
Phantom Share Units
The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. PSUs granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. PSUs vest annually over a or three-year period. The cash-settled PSUs are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period.
The following table summarizes PSU activity for the nine months ended September 30, 2026:
| Number of phantom share units (000's) | Value of share equivalents(1) | |||||||||||||
| Balance December 31, 2025 | $ | |||||||||||||
| Issued | ||||||||||||||
| Vested | ( | ( | ||||||||||||
Forfeited | ( | ( | ||||||||||||
| Balance September 30, 2026 | $ | |||||||||||||
(1)The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company’s common shares at that time, the value of issued share equivalents is based on the market price of the Company’s common shares at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, and the values of forfeited share equivalents and outstanding share equivalents at the end of the period are based on the market price of the Company's common shares at the end of the period. The market price of the Company's common shares was $9.10 and $7.43 on September 30, 2026 and December 31, 2025, respectively.
The change in fair value of the PSUs has been charged to the Condensed Consolidated Statements of Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities. The total liability associated with PSUs at September 30, 2026 is $2.9 million, with $2.0 million of this amount included in current accrued liabilities and the remaining portion of $0.9 million included in long-term accrued liabilities.
The impact associated with the fair value re-measurement of PSUs is recorded in selling, general and administrative expenses within the unaudited Condensed Consolidated Statements of Income. The following table summarizes expense associated with the PSUs for the three and nine months ended September 30, 2026 and 2025 (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Selling, general, and administrative | $ | $ | $ | $ | ||||||||||||||||||||||
The Company paid cash settlements of $2.0 million and $1.8 million during the nine months ended September 30, 2026 and 2025, respectively, pertaining to vestings of cash-settled PSUs.
Page 21 | ||||||||
8. Commitments and Contingencies
The Company accrues estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies (“ASC 450”). No less than quarterly, the Company reviews the status of each significant matter underlying a legal proceeding or claim and assesses its potential financial exposure. The Company accrues a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to the Company at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause the Company to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and the Company may incur substantial costs and expenses defending any of these matters.
Legal Proceedings
From time to time, the Company is involved in legal proceedings arising in the ordinary course of business. As of September 30, 2026, the Company has recognized liabilities for certain matters where losses are probable and reasonably estimable. Based on management's evaluation, the amounts recognized and any reasonably possible additional losses associated with these proceedings are not material, individually or in the aggregate, to the Company's consolidated financial statements. A separate governmental and regulatory matter for which a loss is reasonably possible is discussed below.
Governmental and Regulatory Matters
As a healthcare provider participating in governmental healthcare programs, the Company is subject, in the ordinary course of business, to inspections, prepayment and post-payment reviews, audits and investigations conducted by government agencies and their contractors relating to claims submitted for reimbursement and compliance with applicable program requirements. These matters may require the Company to incur costs to respond to requests for records and pursue appeals of payment denials and may result in adjustments to, or recoupment of, amounts previously reimbursed. Adverse findings may also result in civil or criminal fines, penalties, or other sanctions, including restrictions or changes in the way the Company conducts business, loss of licensure, or exclusion from participation in government healthcare programs.
In July 2025, Qlarant Integrity Solutions, LLC, acting as a Unified Program Integrity Contractor for CMS, issued an audit determination regarding certain Medicare claims submitted by Sleep Management, LLC, a subsidiary of the Company, for monthly rental of non-invasive home ventilators. Qlarant extrapolated an alleged overpayment of approximately $5.9 million. The Company disagrees with the audit findings and believes the claims were reasonable, medically necessary, and supported by appropriate documentation.
The Company timely pursued the Medicare administrative appeals process. As a result of the appeal process to date, the asserted overpayment was reduced to approximately $2.2 million. Following a partially favorable administrative law judge decision in June 2026, the Company appealed the remaining adverse findings to the Medicare Appeals Council in August 2026, where the matter remains pending. The Company continues to dispute the remaining asserted overpayment and intends to pursue further available appeal rights. The Company remitted payment in April 2026 to avoid administrative recoupment, and such payment does not represent a settlement, concession, or admission of liability. The payment is recorded within Prepaid expenses and other assets. Based on information currently available, the Company estimates the reasonably possible loss associated with this matter to range from zero to approximately $2.2 million. The Company has determined that a loss is not probable, and no related accrual has been recorded.
Page 22 | ||||||||
9. Income Taxes
For the nine months ended September 30, 2026, the Company recorded income tax expense of $4.5 million, which includes a discrete tax expense of approximately $0.1 million associated with stock-based compensation arrangements. The effective rate for the nine months ended September 30, 2026 is 30.2 %. The effective tax rate differs from the rate computed by applying the statutory federal and state income tax rates to ordinary income before the provision for income taxes due to permanent non-deductible differences. The Company's effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year.
At September 30, 2026 and 2025, the Company had no
The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.
Page 23 | ||||||||
10. Earnings Per Share
Income per common share is calculated using earnings for the period divided by the weighted average number of shares outstanding during the period. Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and the vesting of RSUs are used to purchase common shares at the prevailing market rate.
The following reflects the earnings and share data used in the basic and diluted earnings per share computations:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Numerator - basic and diluted: | ||||||||||||||||||||||||||
| Net income attributable to Viemed Healthcare, Inc. | $ | $ | $ | $ | ||||||||||||||||||||||
| Denominator: | ||||||||||||||||||||||||||
| Basic weighted-average number of common shares | ||||||||||||||||||||||||||
| Diluted weighted-average number of shares | ||||||||||||||||||||||||||
| Basic earnings per share | $ | $ | $ | $ | ||||||||||||||||||||||
| Diluted earnings per share | $ | $ | $ | $ | ||||||||||||||||||||||
| Denominator calculation from basic to diluted: | ||||||||||||||||||||||||||
| Basic weighted-average number of common shares | ||||||||||||||||||||||||||
| Stock options and other dilutive securities | ||||||||||||||||||||||||||
| Diluted weighted-average number of shares | ||||||||||||||||||||||||||
Anti-dilutive shares excluded from the calculation consisted of employee stock options and RSUs that were de minimis in all periods presented.
11. Subsequent Events
Page 24 | ||||||||
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with, and is qualified entirely by, our condensed consolidated financial statements (including Notes to the Condensed Consolidated Financial Statements) and the other consolidated financial information under Item 1 of this Quarterly Report on Form 10-Q. Some of the information in this discussion and analysis includes forward-looking statements that involve risks and uncertainties. Actual results and timing of events could differ from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Forward-Looking Statements
Certain statements and information in this Quarterly Report on Form 10-Q may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Any statements other than statements of historical information, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. These forward-looking statements are made as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except as required by applicable law.
Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management regarding future events, and include, but are not limited to, statements with respect to: operating results; profitability; financial condition and resources; anticipated needs for working capital; liquidity; capital resources; capital expenditures; milestones; licensing milestones; information with respect to future growth and growth strategies; anticipated trends in our industry; our future financing plans; timelines; currency fluctuations; government regulation; unanticipated expenses; commercial disputes or claims; limitations on insurance coverage or other reimbursement; and availability of cash flow to fund capital requirements. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology.
Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable. We cannot assure you, however, that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, including those identified under “Item 1A. Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and the other documents we file with the SEC, including under “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, and with the securities regulatory authorities in certain provinces of Canada, which contribute to the possibility that the predicted outcomes may not occur or may be delayed. The risks, uncertainties and other factors, many of which are beyond our control, that could influence actual results include, but are not limited to: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; changes in U.S. trade policies and retaliatory responses from other countries, including tariffs; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new laws and regulations and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; the use of artificial intelligence technologies; as well as other general economic, market and business conditions; and other factors beyond our control.
Page 25 | ||||||||
General Matters
In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms the "Company," "we," "us" and "our" refer to Viemed Healthcare, Inc. and its subsidiaries in which it has a controlling financial interest.
We were incorporated on December 14, 2016 pursuant to the Business Corporations Act (British Columbia). As of June 30, 2020, we determined that we no longer qualify as a "foreign private issuer," as defined in Rule 3b-4 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for the purposes of the informational requirements of the Exchange Act. As a result, effective January 1, 2021, we became subject to the proxy solicitation rules under Section 14 of the Exchange Act and Regulation FD, and our officers, directors, and principal shareholders became subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. We will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the SEC and with the relevant Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval (SEDAR).
Overview
We provide an array of home medical equipment, services and supplies, specializing in post-acute respiratory care services in the United States. Our primary objective is to drive growth by increasing the number of patients served and the level of care provided through our technology-enabled, home-based clinical care and chronic disease management model. Our care programs are designed specifically to treat patients in the home for less total cost and with a superior quality of care. Our services include respiratory disease management (through the rental of various HME devices), neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, the sale of associated supplies, women’s health products and services, and healthcare staffing services.
We derive a significant portion of our revenue through the rental of non-invasive and invasive ventilators, which represented 46.4% and 48.5% of our revenue for the three months ended September 30, 2026 and 2025, respectively, and 46.6% and 52.0% for the nine months ended September 30, 2026 and 2025, respectively. We combine the benefits of home ventilation support with licensed Respiratory Therapists ("RTs") to drive improved patient outcomes and reduce costly hospital readmissions.
We expect to grow through expansion of existing service areas as well as in new territories through a cost efficient launch that reduces location expenses. We currently serve patients in all 50 states. We expect to expand our workforce of licensed clinical practitioners, including RTs, to support our growth and ensure the high service model is maintained in the home. As of September 30, 2026, we employed 432 licensed RTs, representing approximately 29% of our company-wide employee count. Beyond fulfilling our internal staffing needs, we also provide healthcare staffing and recruitment services, offering tailored workforce solutions to external healthcare institutions and partners seeking qualified clinical professionals.
By focusing overhead costs on personnel that service the patient rather than physical location costs, we anticipate that we will efficiently scale our business in territories that are currently not being effectively serviced.
The continued trend of servicing patients in the home rather than in hospitals is aligned with our business objective and we anticipate that this trend will continue to offer growth opportunities for us. We expect to continue to be a solution to the rising health costs in the United States by offering more cost effective, home based solutions while increasing the quality of life for patients managing chronic and complex health conditions.
Page 26 | ||||||||
Trends Affecting Our Business
Demographic and Market Trends
Home medical equipment markets are witnessing sustained expansion, with a notable focus on the complex respiratory and Obstructive Sleep Apnea ("OSA") device segments. Analysts in the industry anticipate a consistent and robust growth trajectory, projecting Compound Annual Growth Rates ("CAGR") of approximately 6% for respiratory devices and 8% for OSA devices. This upward trend underscores the increasing demand for innovative solutions in respiratory care and sleep apnea management, highlighting the industry's responsiveness to evolving healthcare needs. As technological advancements and awareness drive the adoption of these specialized devices, we believe the HME markets, particularly in respiratory and OSA, are positioned for continuous expansion, offering promising opportunities for both providers and consumers alike.
The aging population remains a pivotal driver for the industry, as the elderly, constituting a substantial portion of HME patients, are expected to represent a higher percentage of the overall population. Projections from industry analysts indicate a consistent annual growth in the number of Medicare beneficiaries, contributing to ongoing patient volume growth. A significant contributing factor to the industry's growth is the rising incidence of chronic diseases. Factors such as increasing obesity rates, consequences of past smoking prevalence, under-diagnosis of certain health conditions, and higher diagnosis rates for chronic diseases collectively shape the industry. There is a notable shift towards home-based treatment for these conditions.
The industry is undergoing a transition to value-based healthcare, with both government and commercial payors increasingly adopting models that emphasize the transition of patients from acute care settings to home care. We believe HME providers are well-positioned to benefit from this industry shift. Advancements in technology and medical equipment have led to an increased prevalence of in-home treatments. The broader range of treatments administered in patient homes is expected to continue growing. Projections from industry analysts indicate that U.S. home healthcare spending will increase, reaching $250 billion by 2031, with a CAGR of approximately 7%.
Market consolidation is a notable trend favoring larger, financially stable players. The decline in the number of smaller regional players is attributed to the capital investment and scale required to compete effectively. This has led to a more consolidated and competitive landscape in the durable medical equipment (“DME”) market.
Despite these positive trends, the industry faces challenges such as cost containment efforts of payors. The consolidation of managed care payors into larger purchasing groups has increased negotiating power, resulting in pricing pressure on HME providers. In addition to ongoing negotiations relating to contract management with third party payors to secure fair reimbursement, HME providers are engaging in value-based contracting, focusing on outcomes and patient satisfaction. These value-based contracts leverage data analytics to demonstrate the cost-effectiveness and quality of durable medical goods and provide evidence-based data to payors demonstrating the long-term benefits and cost savings associated with the use of certain medical goods.
Regulatory and Policy Developments
Regulatory and policy developments remain a key area of focus. In particular, ventilator coverage has received renewed attention from the Centers for Medicare & Medicaid Services (“CMS”). Although ventilators have historically been included under the National Coverage Determination (“NCD”) for the Durable Medical Equipment Reference List, there was previously no dedicated policy specifically addressing ventilator use. On September 11, 2024, CMS initiated a national coverage analysis to evaluate noninvasive positive pressure ventilation in the home for the treatment of chronic respiratory failure associated with chronic obstructive pulmonary disease. CMS issued a proposed decision memorandum on March 11, 2025, followed by a final NCD on June 9, 2025. We actively participated in this process through formal comments and engagement with CMS, the U.S. Department of Health and Human Services (“HHS”), and members of Congress. The final NCD establishes specific medical necessity criteria for ventilator use that are expected to influence patient access, reimbursement, and utilization patterns. In addition to affecting traditional Medicare, the NCD may also influence coverage determinations and reimbursement policies under commercial insurance and Medicare Advantage plans that reference or align with CMS coverage criteria. These changes may have a material impact on our business.
In November 2025, CMS finalized changes to the Medicare Competitive Bidding Program for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (“DMEPOS”), including revisions to payment methodologies, contract award processes, and the establishment of a nationwide Remote Item Delivery program for selected product categories. The next competitive bidding round is scheduled to begin January 1, 2028, with bidding scheduled to open in January 2027. The announced product categories do not include ventilators, positive airway pressure therapy equipment, or oxygen equipment. Separately, CMS finalized changes to
Page 27 | ||||||||
DMEPOS supplier accreditation and Medicare enrollment requirements, including a transition to annual surveys and reaccreditation. These requirements apply more broadly than the product categories selected for competitive bidding and may increase compliance costs. We continue to monitor implementation of these changes and potential future expansions of competitive bidding, which could affect reimbursement rates, supplier participation, and our operations.
The federal budget reconciliation legislation, known as the One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, introduces a broad set of statutory and policy changes that may affect the healthcare industry and our operations. Key provisions include revisions to Medicaid renewal and eligibility rules, adjustments to Medicaid state-directed payments and provider tax frameworks, new cost-sharing requirements, reduced home equity thresholds for long-term care eligibility, expanded telehealth coverage, and state waivers to support home and community-based services. The OBBBA also establishes a Rural Health Transformation program aimed at improving access and care coordination in underserved communities. Implementation of Pay-As-You-Go (“PAYGO”) rules could result in future adjustments to Medicare and Medicaid spending, including cost containment measures or payment reductions that may impact providers. Most provisions are scheduled to take effect in 2027 and 2028, although some states may elect to implement certain measures as early as 2026. We continue to monitor these regulatory developments closely.
Cost Pressures
Viemed operates in an environment of ongoing cost pressures from general cost increases, supply chain dynamics, and government policy. Manufacturing and distribution expenses are influenced by factors such as rising material, labor, and transportation costs, including fuel.
As discussed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 4, 2026, we are primarily exposed to trade policy and tariff developments indirectly, through supplier pricing and component sourcing rather than direct import activity. While certain medical equipment and components have historically been excluded from tariff regimes or subject to exemptions, trade measures may be expanded, reclassified, or implemented with limited notice, and suppliers may increase prices to reflect higher input costs, compliance requirements, or logistics constraints. These developments could increase our equipment and supply costs and reduce product availability. To date, we have not experienced a material adverse impact on operating costs or supply availability attributable to tariffs. However, the timing, scope, and duration of future actions remain uncertain, and we continue to monitor these developments and evaluate their potential operational and financial effects.
Future volatility in general price inflation and its impact on material availability, shipping, warehousing, and operational overhead could further impact financial results. Viemed attempts to manage these pressures through its inflation-linked reimbursement contracts, negotiation, leveraging its purchasing power, and embracing technology, such as its proprietary clinical management platform.
Page 28 | ||||||||
The below table highlights summary financial and operational metrics for the last eight quarters.
| (Tabular amounts expressed in thousands of U.S. Dollars, except operational information) | ||||||||||||||||||||||||||
| For the quarter ended | September 30, 2026 | June 30, 2026 | March 31, 2026 | December 31, 2025 | September 30, 2025 | June 30, 2025 | March 31, 2025 | December 31, 2024 | ||||||||||||||||||
| Financial Information: | ||||||||||||||||||||||||||
| Revenue | $ | 80,673 | $ | 78,097 | $ | 75,414 | $ | 76,181 | $ | 71,914 | $ | 63,056 | $ | 59,129 | $ | 60,695 | ||||||||||
| Gross Profit | $ | 46,192 | $ | 45,048 | $ | 42,827 | $ | 44,103 | $ | 41,345 | $ | 36,731 | $ | 33,279 | $ | 36,138 | ||||||||||
| Gross Profit % | 57 | % | 58 | % | 57 | % | 58 | % | 57 | % | 58 | % | 56 | % | 60 | % | ||||||||||
| Net Income attributable to Viemed Healthcare, Inc. | $ | 4,638 | $ | 2,764 | $ | 2,582 | $ | 5,639 | $ | 3,513 | $ | 3,157 | $ | 2,625 | $ | 4,316 | ||||||||||
| Cash and Cash Equivalents (As of) | $ | 9,676 | $ | 10,680 | $ | 9,762 | $ | 13,501 | $ | 11,123 | $ | 20,016 | $ | 10,160 | $ | 17,540 | ||||||||||
| Total Assets (As of) | $ | 207,634 | $ | 204,224 | $ | 197,361 | $ | 199,154 | $ | 202,360 | $ | 184,603 | $ | 178,079 | $ | 177,069 | ||||||||||
Adjusted EBITDA(1) | $ | 17,057 | $ | 13,715 | $ | 14,311 | $ | 18,203 | $ | 16,121 | $ | 14,287 | $ | 12,765 | $ | 14,242 | ||||||||||
| Operational Information: | ||||||||||||||||||||||||||
Vent Patients(2) | 12,552 | 12,635 | 12,089 | 12,259 | 12,372 | 12,152 | 11,809 | 11,795 | ||||||||||||||||||
PAP Therapy Patients(3) | 43,861 | 37,825 | 35,938 | 34,528 | 31,891 | 26,260 | 22,899 | 21,338 | ||||||||||||||||||
Sleep Resupply Patients(4) | 40,918 | 37,035 | 33,661 | 36,561 | 33,518 | 25,246 | 22,941 | 24,478 | ||||||||||||||||||
(1) Refer to "Non-GAAP Financial Measures" section below for definition of Adjusted EBITDA.
(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.
(3) PAP Therapy Patients represents the number of distinct patients billed for PAP therapy services during each calendar quarter.
(4) Sleep Resupply Patients represents the number of distinct patients who received supplies through our sleep resupply program during each calendar quarter.
Page 29 | ||||||||
Results of Operations
Comparison of the Three Months Ended September 30, 2026 and 2025:
The following table summarizes our results of operations for the three months ended September 30, 2026 and 2025:
| Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
| 2026 | % of Total Revenue | 2025 | % of Total Revenue | $ Change | % Change | ||||||||||||||||||||||||||||||
| Revenue | $ | 80,673 | 100.0 | % | $ | 71,914 | 100.0 | % | $ | 8,759 | 12.2 | % | |||||||||||||||||||||||
| Cost of revenue | 34,481 | 42.7 | % | 30,569 | 42.5 | % | 3,912 | 12.8 | % | ||||||||||||||||||||||||||
| Gross profit | 46,192 | 57.3 | % | 41,345 | 57.5 | % | 4,847 | 11.7 | % | ||||||||||||||||||||||||||
| Selling, general and administrative | 35,508 | 44.0 | % | 31,919 | 44.4 | % | 3,589 | 11.2 | % | ||||||||||||||||||||||||||
| Research and development | 501 | 0.6 | % | 775 | 1.1 | % | (274) | (35.4) | % | ||||||||||||||||||||||||||
| Stock-based compensation | 2,476 | 3.1 | % | 2,180 | 3.0 | % | 296 | 13.6 | % | ||||||||||||||||||||||||||
Depreciation and amortization | 392 | 0.5 | % | 397 | 0.6 | % | (5) | (1.3) | % | ||||||||||||||||||||||||||
| Loss (gain) on disposal of property and equipment | 412 | 0.5 | % | 476 | 0.7 | % | (64) | (13.4) | % | ||||||||||||||||||||||||||
| Other income, net | (59) | (0.1) | % | (44) | (0.1) | % | (15) | 34.1 | % | ||||||||||||||||||||||||||
| Income from operations | 6,962 | 8.6 | % | 5,642 | 7.8 | % | 1,320 | 23.4 | % | ||||||||||||||||||||||||||
| Non-operating income and expenses | |||||||||||||||||||||||||||||||||||
Interest expense, net | 177 | 0.2 | % | 507 | 0.7 | % | (330) | (65.1) | % | ||||||||||||||||||||||||||
| Net income before taxes | 6,785 | 8.4 | % | 5,135 | 7.1 | % | 1,650 | 32.1 | % | ||||||||||||||||||||||||||
Provision for income taxes | 2,048 | 2.5 | % | 1,535 | 2.1 | % | 513 | 33.4 | % | ||||||||||||||||||||||||||
| Net income | 4,737 | 5.9 | % | 3,600 | 5.0 | % | 1,137 | 31.6 | % | ||||||||||||||||||||||||||
| Net income attributable to noncontrolling interest | 99 | 0.1 | % | 87 | 0.1 | % | 12 | 13.8 | % | ||||||||||||||||||||||||||
| Net income attributable to Viemed Healthcare, Inc. | $ | 4,638 | 5.7 | % | $ | 3,513 | 4.9 | % | $ | 1,125 | 32.0 | % | |||||||||||||||||||||||
Revenue
The following table summarizes our revenue for the three months ended September 30, 2026 and 2025:
| Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
| 2026 | % of Total Revenue | 2025 | % of Total Revenue | $ Change | % Change | ||||||||||||||||||||||||||||||
Revenue from rentals | |||||||||||||||||||||||||||||||||||
| Ventilator rentals, non-invasive and invasive | $ | 37,460 | 46.4 | % | $ | 34,883 | 48.5 | % | $ | 2,577 | 7.4 | % | |||||||||||||||||||||||
| Other home medical equipment rentals | 17,414 | 21.6 | % | 15,401 | 21.4 | % | 2,013 | 13.1 | % | ||||||||||||||||||||||||||
Revenue from sales and services | |||||||||||||||||||||||||||||||||||
| Equipment and supply sales | 19,414 | 24.1 | % | 15,700 | 21.8 | % | 3,714 | 23.7 | % | ||||||||||||||||||||||||||
| Service revenues | 6,385 | 7.9 | % | 5,930 | 8.3 | % | 455 | 7.7 | % | ||||||||||||||||||||||||||
Total revenue | $ | 80,673 | 100.0 | % | $ | 71,914 | 100.0 | % | $ | 8,759 | 12.2 | % | |||||||||||||||||||||||
For the three months ended September 30, 2026, total revenue was $80.7 million, an increase of $8.8 million, or 12.2%, compared to the three months ended September 30, 2025. The increase was driven by growth across our rental, equipment and supply sales, and service revenue categories, primarily reflecting continued growth in sleep therapy, complex respiratory care, and women’s health products and services.
Revenue from non-invasive and invasive ventilator rentals increased by $2.6 million, or 7.4%, to $37.5 million for the three months ended September 30, 2026. The increase was primarily attributable to higher average patient volumes, reflecting continued demand for home non-invasive ventilation services. Rental revenue from other home medical equipment increased by $2.0 million, or 13.1%, to $17.4 million for the three months ended September 30, 2026. The increase was driven primarily by growth in PAP therapy and airway-clearance services.
Page 30 | ||||||||
Equipment and supply sales increased by $3.7 million, or 23.7%, to $19.4 million for the three months ended September 30, 2026. The increase was primarily attributable to higher PAP resupply volumes and continued growth in women’s health product sales, including breast pumps and related supplies. Service revenues, which consist primarily of revenue from our healthcare staffing operations and in-home sleep testing services, increased by $0.5 million, or 7.7%, to $6.4 million for the three months ended September 30, 2026.
Ventilator rentals remained our largest individual source of revenue. However, the growth of PAP therapy and resupply, women’s health, airway-clearance services, and other home medical equipment offerings continued to diversify our revenue mix.
Cost of revenue and gross profit
For the three months ended September 30, 2026, cost of revenue totaled $34.5 million, an increase of $3.9 million, or 12.8%, from the comparable period in 2025. The increase was primarily attributable to higher patient volumes and equipment and supply sales, reflecting continued growth across our sleep therapy, resupply, and women’s health offerings.
Gross profit increased $4.8 million, or 11.7%, to $46.2 million for the three months ended September 30, 2026, compared to $41.3 million in the comparable period in 2025. Gross profit margin remained relatively stable at 57.3% for the three months ended September 30, 2026, compared to 57.5% for the three months ended September 30, 2025. The modest decrease primarily reflected a shift in revenue mix toward equipment and supply sales, which generally carry lower gross margins than equipment rentals but require less capital investment. For the three months ended September 30, 2026, revenue from sales and services represented 32.0% of total revenue, compared to 30.1% in the comparable period in 2025.
Selling, general and administrative expense
Selling, general, and administrative expenses as a percentage of revenue modestly improved to 44.0% for the three months ended September 30, 2026, compared to 44.4% for the three months ended September 30, 2025. Selling, general and administrative expenses totaled $35.5 million for the three months ended September 30, 2026, an increase of $3.6 million, or 11.2%, from the comparable period in 2025.
The increase in selling, general and administrative expense was primarily attributable to expenses incurred to support the continued growth of the business, including higher personnel costs and continued investments in technology and operational infrastructure. Employee compensation and related expenses increased $2.4 million, or 11.9%, primarily reflecting increased staffing levels to support growth in patient volumes and business operations. Other factors contributing to the increase included approximately $0.7 million of incremental expenses related to technology and software investments, $0.4 million of increased marketing expenses associated with the expansion of our women's health offerings, and $0.3 million of higher legal and professional fees. These increases were partially offset by approximately $0.8 million of acquisition-related transaction costs incurred in the prior-year period that did not recur in 2026 and a $0.3 million reduction in phantom share compensation expense.
The decrease in selling, general and administrative expenses as a percentage of revenue reflected continued revenue growth and operating leverage, notwithstanding ongoing investments in technology, personnel, and infrastructure to support the expansion of our operations.
Research and development
For the three months ended September 30, 2026, research and development expense totaled $0.5 million, a decrease of $0.3 million, or 35.4%, from $0.8 million in the comparable period in 2025. We expect research and development costs to remain consistent throughout the remainder of 2026 as we continue to invest in technology initiatives to support our clinical operations and service delivery capabilities.
Stock-based compensation
For the three months ended September 30, 2026, stock-based compensation totaled $2.5 million, an increase of 13.6% from the comparable period in 2025. Stock-based compensation continues to reflect our ongoing investment in employee retention and long-term incentive programs through the use of equity-based awards, with expense recognized over the respective vesting periods of awards granted in both the current and prior years.
Loss (gain) on disposal of property and equipment
For the three months ended September 30, 2026, loss on disposal of property and equipment was $0.4 million, compared to a loss on disposal of property and equipment of $0.5 million for the three months ended September 30, 2025. The losses recognized in both periods primarily related to the disposal of equipment in the ordinary course of business, including equipment that was damaged or destroyed, and similar losses may continue to occur in future periods.
Page 31 | ||||||||
Provision for income taxes
For the three months ended September 30, 2026, the provision for income taxes was a $2.0 million expense, compared to a $1.5 million expense during the comparable 2025 period. Our annual estimated effective tax rate for 2026 is 30.2%.
Net income
For the three months ended September 30, 2026, net income was $4.7 million, an increase of $1.1 million, or 31.6% from the comparable period in 2025. Net income represented 5.9% of revenue for the 2026 period, compared to 5.0% for the 2025 period. The increase was primarily attributable to higher gross profit resulting from continued revenue growth, partially offset by increased operating expenses and a higher provision for income taxes.
Page 32 | ||||||||
Comparison of the Nine Months Ended September 30, 2026 and 2025:
The following table summarizes our results of operations for the nine months ended September 30, 2026 and 2025:
| Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||
| 2026 | % of Total Revenue | 2025 | % of Total Revenue | $ Change | % Change | ||||||||||||||||||||||||||||||
| Revenue | $ | 234,184 | 100.0 | % | $ | 194,099 | 100.0 | % | $ | 40,085 | 20.7 | % | |||||||||||||||||||||||
| Cost of revenue | 100,117 | 42.8 | % | 82,744 | 42.6 | % | 17,373 | 21.0 | % | ||||||||||||||||||||||||||
| Gross profit | 134,067 | 57.2 | % | 111,355 | 57.4 | % | 22,712 | 20.4 | % | ||||||||||||||||||||||||||
| Selling, general and administrative | 107,432 | 45.9 | % | 89,147 | 45.9 | % | 18,285 | 20.5 | % | ||||||||||||||||||||||||||
| Research and development | 1,584 | 0.7 | % | 2,419 | 1.2 | % | (835) | (34.5) | % | ||||||||||||||||||||||||||
| Stock-based compensation | 6,959 | 3.0 | % | 6,832 | 3.5 | % | 127 | 1.9 | % | ||||||||||||||||||||||||||
Depreciation and amortization | 1,168 | 0.5 | % | 1,098 | 0.6 | % | 70 | 6.4 | % | ||||||||||||||||||||||||||
| Loss (gain) on disposal of property and equipment | 1,366 | 0.6 | % | (2,528) | (1.3) | % | 3,894 | (154.0) | % | ||||||||||||||||||||||||||
| Other income, net | (161) | (0.1) | % | (191) | (0.1) | % | 30 | (15.7) | % | ||||||||||||||||||||||||||
| Income from operations | 15,719 | 6.7 | % | 14,578 | 7.5 | % | 1,141 | 7.8 | % | ||||||||||||||||||||||||||
Non-operating income and expenses | |||||||||||||||||||||||||||||||||||
| Loss from investments | 162 | 0.1 | % | — | — | % | 162 | NM | |||||||||||||||||||||||||||
Interest expense, net | 730 | 0.3 | % | 818 | 0.4 | % | (88) | (10.8) | % | ||||||||||||||||||||||||||
| Net income before taxes | 14,827 | 6.3 | % | 13,760 | 7.1 | % | 1,067 | 7.8 | % | ||||||||||||||||||||||||||
| Provision for income taxes | 4,477 | 1.9 | % | 4,200 | 2.2 | % | 277 | 6.6 | % | ||||||||||||||||||||||||||
| Net income | 10,350 | 4.4 | % | 9,560 | 4.9 | % | 790 | 8.3 | % | ||||||||||||||||||||||||||
| Net income attributable to noncontrolling interest | 366 | 0.2 | % | 265 | 0.1 | % | 101 | 38.1 | % | ||||||||||||||||||||||||||
| Net income attributable to Viemed Healthcare, Inc. | $ | 9,984 | 4.3 | % | $ | 9,295 | 4.8 | % | $ | 689 | 7.4 | % | |||||||||||||||||||||||
Revenue
The following table summarizes our revenue for the nine months ended September 30, 2026 and 2025:
| Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||
| 2026 | % of Total Revenue | 2025 | % of Total Revenue | $ Change | % Change | ||||||||||||||||||||||||||||||
Revenue from rentals | |||||||||||||||||||||||||||||||||||
| Ventilator rentals, non-invasive and invasive | $ | 109,231 | 46.6 | % | $ | 100,862 | 52.0 | % | $ | 8,369 | 8.3 | % | |||||||||||||||||||||||
Other home medical equipment rentals | 50,020 | 21.4 | % | 42,199 | 21.7 | % | 7,821 | 18.5 | % | ||||||||||||||||||||||||||
Revenue from sales and services | |||||||||||||||||||||||||||||||||||
| Equipment and supply sales | 55,873 | 23.9 | % | 32,720 | 16.9 | % | 23,153 | 70.8 | % | ||||||||||||||||||||||||||
| Service revenues | 19,060 | 8.1 | % | 18,318 | 9.4 | % | 742 | 4.1 | % | ||||||||||||||||||||||||||
Total revenue | $ | 234,184 | 100.0 | % | $ | 194,099 | 100.0 | % | $ | 40,085 | 20.7 | % | |||||||||||||||||||||||
For the nine months ended September 30, 2026, total revenue was $234.2 million, an increase of $40.1 million, or 20.7%, compared to the nine months ended September 30, 2025. The increase was driven by growth across our rental, equipment and supply sales, and service revenue categories, primarily reflecting continued expansion of our sleep therapy, complex respiratory care, and women’s health offerings, as well as the inclusion of nine months of revenue from Lehan Drugs, Inc. (“Lehan”) compared to three months in the prior-year period.
Revenue from non-invasive and invasive ventilator rentals increased by $8.4 million, or 8.3%, to $109.2 million for the nine months ended September 30, 2026. The increase was primarily attributable to higher average patient volumes and continued demand for home non-invasive ventilation services. Rental revenue from other home medical equipment increased by $7.8 million, or 18.5%, to $50.0 million for the nine months ended September 30, 2026. The increase was primarily driven by growth in PAP therapy and airway-clearance services, as well as rental revenue associated with women’s health products and Lehan operations.
Page 33 | ||||||||
Equipment and supply sales increased by $23.2 million, or 70.8%, to $55.9 million for the nine months ended September 30, 2026. The increase was primarily attributable to the additional contribution from Lehan, continued growth in women’s health product sales, including breast pumps and related supplies, and higher PAP resupply volumes reflecting expansion of our sleep therapy patient base. Service revenues, which consist primarily of revenue from our healthcare staffing operations and in-home sleep testing services, increased by $0.7 million, or 4.1%, to $19.1 million for the nine months ended September 30, 2026.
Ventilator rentals remained our largest individual source of revenue. However, continued growth across PAP therapy and resupply, women’s health, airway-clearance services, and other home medical equipment offerings further diversified our revenue mix, with ventilator rentals representing 46.6% of total revenue compared to 52.0% in the prior-year period.
Cost of revenue and gross profit
For the nine months ended September 30, 2026, cost of revenue totaled $100.1 million, an increase of $17.4 million, or 21.0%, from the comparable period in 2025. The increase was primarily attributable to higher patient volumes and equipment and supply sales, reflecting continued growth across our sleep therapy, resupply, and women's health offerings, as well as the inclusion of nine months of Lehan operations compared to three months in the prior-year period.
Gross profit increased $22.7 million, or 20.4%, to $134.1 million for the nine months ended September 30, 2026, compared to $111.4 million in the comparable period in 2025. Gross profit margin remained relatively stable at 57.2%, compared to 57.4% in the prior-year period. The modest decrease primarily reflected a shift in revenue mix toward equipment and supply sales, which generally carry lower gross margins than equipment rentals but require less capital investment. For the nine months ended September 30, 2026, revenue from sales and services represented 32.0% of total revenue, compared to 26.3% in the comparable period in 2025.
Selling, general and administrative expense
Selling, general, and administrative expenses as a percentage of revenue were unchanged at 45.9% for the nine months ended September 30, 2026 and September 30, 2025. Selling, general and administrative expenses totaled $107.4 million for the nine months ended September 30, 2026, an increase of $18.3 million, or 20.5%, from the comparable period in 2025.
The increase in selling, general and administrative expense was primarily attributable to costs incurred to support continued business growth, including the additional six months of Lehan operations compared to the prior-year period. Employee compensation and related expenses increased approximately $9.9 million, primarily reflecting higher staffing levels to support increased patient volumes and expanded operations. Other contributing factors included $1.6 million of higher billing expenses associated with increased claims volume, $1.8 million of higher technology and software expenses, $1.1 million of increased marketing expenses, and $1.0 million of higher phantom share compensation expense, primarily driven by changes in our share price. These increases were partially offset by approximately $0.9 million of lower acquisition-related transaction costs.
Selling, general and administrative expenses remained consistent as a percentage of revenue, reflecting continued revenue growth while supporting investments in personnel, technology, and operating capacity.
Research and development
For the nine months ended September 30, 2026, research and development expense totaled $1.6 million, a decrease of $0.8 million, or 34.5%, from $2.4 million in the comparable period in 2025. We expect research and development costs to remain consistent throughout the remainder of 2026 as we continue to invest in technology initiatives to support our clinical operations and service delivery capabilities.
Stock-based compensation
For the nine months ended September 30, 2026, stock-based compensation totaled $7.0 million, an increase of 1.9% from the comparable period in 2025. Stock-based compensation continues to reflect our ongoing investment in employee retention and long-term incentive programs through the use of equity-based awards, with expense recognized over the respective vesting periods of awards granted in both the current and prior years.
Loss (gain) on disposal of property and equipment
For the nine months ended September 30, 2026, loss on disposal of property and equipment totaled $1.4 million, compared to a gain on disposal of property and equipment of $2.5 million for the nine months ended September 30, 2025. The gain recognized in the prior-year period was primarily attributable to proceeds received from the sale of recalled ventilators to the manufacturer in excess of their net book value. The loss recognized in 2026 primarily reflected equipment disposals in the ordinary course of business.
Page 34 | ||||||||
The ventilator buyback program was substantially completed in 2025, and accordingly we do not expect additional material gains from these transactions in future periods. We may, however, continue to recognize gains or losses from the disposal of equipment in the ordinary course of business, including losses related to damaged or destroyed equipment.
Provision for income taxes
For the nine months ended September 30, 2026, the provision for income taxes was a $4.5 million expense, compared to a $4.2 million expense during the 2025 period. Our annual estimated effective tax rate for 2026 is 30.2%.
Net income
Net income was $10.4 million for the nine months ended September 30, 2026, an increase of $0.8 million, or 8.3%, compared to $9.6 million for the nine months ended September 30, 2025. Net income represented 4.4% of revenue for the 2026 period, compared to 4.9% for the 2025 period. The increase in net income was primarily attributable to higher gross profit resulting from continued revenue growth, partially offset by increased selling, general and administrative expenses and the absence of gains associated with the ventilator buyback program recognized in the prior-year period.
Page 35 | ||||||||
Non-GAAP Financial Measures
The Company uses Adjusted EBITDA, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. It is not a measurement of our financial performance under GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with GAAP or as an alternative to cash flows from operating activities as a measure of the Company's liquidity. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our operating results as reported under GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of ongoing operations; and other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income attributable to Viemed Healthcare, Inc., including depreciation and amortization of capitalized assets, net interest expense, stock based compensation, transaction costs, impairment of assets, and taxes.
The following table is a reconciliation of net income attributable to Viemed Healthcare, Inc., the most directly comparable GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
| For the quarter ended | September 30, 2026 | June 30, 2026 | March 31, 2026 | December 31, 2025 | September 30, 2025 | June 30, 2025 | March 31, 2025 | December 31, 2024 | ||||||||||||||||||
Net income attributable to Viemed Healthcare, Inc. | $ | 4,638 | $ | 2,764 | $ | 2,582 | $ | 5,639 | $ | 3,513 | $ | 3,157 | $ | 2,625 | $ | 4,316 | ||||||||||
| Add back: | ||||||||||||||||||||||||||
Depreciation & amortization | 7,718 | 7,520 | 7,621 | 7,570 | 7,539 | 6,891 | 6,613 | 6,366 | ||||||||||||||||||
Interest expense, net | 177 | 248 | 305 | 364 | 507 | 132 | 179 | 147 | ||||||||||||||||||
Stock-based compensation(a) | 2,476 | 2,032 | 2,451 | 2,300 | 2,180 | 2,341 | 2,311 | 1,521 | ||||||||||||||||||
Transaction costs(b) | — | — | 74 | 139 | 847 | 53 | 85 | 11 | ||||||||||||||||||
Impairment of assets(c) | — | — | — | — | — | — | — | — | ||||||||||||||||||
| Income tax expense | 2,048 | 1,151 | 1,278 | 2,191 | 1,535 | 1,713 | 952 | 1,881 | ||||||||||||||||||
| Adjusted EBITDA | $ | 17,057 | $ | 13,715 | $ | 14,311 | $ | 18,203 | $ | 16,121 | $ | 14,287 | $ | 12,765 | $ | 14,242 | ||||||||||
(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.
(c) Represents impairments of the fair value of investment and litigation-related assets.
Page 36 | ||||||||
Liquidity and Capital Resources
Cash and cash equivalents at September 30, 2026 was $9.7 million, compared to $13.5 million at December 31, 2025. Typically, our principal source of liquidity is the collection of our patient accounts receivable. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity through the incurrence of indebtedness. Based on our current plan of operations, we believe cash and cash equivalents, when combined with expected cash flows from operations and amounts available under our 2022 Senior Credit Facilities will be sufficient to fund our growth strategy and to meet our anticipated operating expenses, capital expenditures, and debt service obligations for at least the next 12 months from the date of this filing. The Company has also historically utilized short term financing arrangements with suppliers that could be extended over a longer term if there was a need for additional liquidity.
On June 6, 2025, the Company's Board of Directors authorized and approved a share repurchase program. Under the terms of this program, the Company repurchased 1,976,441 of its common shares and the program was completed and terminated during 2025. On March 4, 2026, the Company's Board of Directors authorized and approved a new share repurchase program (the “2026 Share Repurchase Program”). Under the terms of the 2026 Share Repurchase Program, the Company may repurchase up to 1,930,131 of its common shares from time to time through open market purchases, block purchases or otherwise in accordance with applicable securities laws, including Rule 10b-18 of the Exchange Act. During the nine months ended September 30, 2026, the Company repurchased and canceled 795,802 common shares pursuant to the 2026 Share Repurchase Program.
Cash Flows
The following table summarizes our cash flows for the periods indicated:
| Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Net Cash provided by (used in): | ||||||||||||||
| Operating activities | $ | 35,460 | $ | 33,475 | ||||||||||
| Investing activities | (20,785) | (42,554) | ||||||||||||
| Financing activities | (18,500) | 2,662 | ||||||||||||
Net decrease in cash and cash equivalents | $ | (3,825) | $ | (6,417) | ||||||||||
Net Cash Provided by Operating Activities
Net cash provided by operating activities during the nine months ended September 30, 2026 was $35.5 million, resulting from net income of $10.4 million, increased by net income adjustments of $31.5 million and partially offset by an increase in non-cash working capital of $6.4 million. The net income adjustments primarily consisted of $22.9 million of depreciation and amortization and $7.0 million of stock-based compensation. The primary changes in non-cash working capital were an increase in net accounts receivable of $9.3 million and an increase in prepaid expenses and other assets of $6.0 million, partially offset by an increase in trade payables of $2.7 million, an increase in accrued liabilities of $3.1 million, and an increase in net income tax payable of $2.2 million.
Net cash provided by operating activities during the nine months ended September 30, 2025 was $33.5 million, resulting from net income of $9.6 million, increased by net income adjustments of $28.2 million and partially offset by an increase in non-cash working capital of $4.3 million. The net income adjustments primarily consisted of $21.0 million of depreciation and amortization, $6.8 million of stock-based compensation, and a $2.7 million deferred income tax expense, partially offset by a $2.5 million gain on disposal of property and equipment. The primary changes in non-cash working capital were an increase in accrued liabilities of $1.6 million and trade payables of $0.8 million, partially offset by a change in income tax payable/receivable of $5.8 million and an increase in net accounts receivable of $0.7 million.
Net Cash Used in Investing Activities
Net cash used in investing activities during the nine months ended September 30, 2026 was $20.8 million. Net cash used for capital expenditures during the period consisted of $23.8 million of purchases of property and equipment, partially offset by $3.6 million of sales proceeds from the disposal of property and equipment. Purchases of property and equipment were primarily related to medical equipment rented to our patients. Net cash used in investing activities also included a $0.6 million equity investment.
Net cash used in investing activities during the nine months ended September 30, 2025 was $42.6 million, primarily due to the net cash paid for the acquisition of Lehan of $26.3 million. Net cash used for capital expenditures during the period was $16.2 million, consisting of $31.2 million of purchases of property and equipment, partially offset by $15.0 million of sales proceeds from the
Page 37 | ||||||||
disposal of property and equipment. Purchases of property and equipment were primarily related to medical equipment rented to our patients.
Net cash used for capital expenditures increased by $4.0 million, or 24.7%, compared to the prior-year period. Although purchases of property and equipment decreased, the reduction was more than offset by lower proceeds from sales of property and equipment, as the prior-year period benefited from proceeds associated with the ventilator return program.
Net Cash Provided by (Used in) Financing Activities
Net cash used in financing activities during the nine months ended September 30, 2026 was $18.5 million. During the nine months ended September 30, 2026, principal payments on the 2022 Term Loan Facility (as defined below) were $7.6 million. In addition, the Company made acquisition-related contingent consideration payments of $1.8 million, paid $7.7 million pursuant to share repurchase programs and canceled 277,390 common shares at a cost of $2.1 million to satisfy employee income tax withholding obligations associated with the vesting of RSUs. These uses of cash were partially offset by $1.1 million of proceeds from the exercise of stock options.
Net cash provided by financing activities during the nine months ended September 30, 2025 was $2.7 million. During the period, proceeds from the 2022 Term Loan Facility were $9.0 million and proceeds from the 2022 Revolving Credit Facility (as defined below) were $13.0 million, which were used to partially fund the cash acquisition of Lehan. Subsequent to the Lehan acquisition, the Company made $5.0 million of principal payments on the 2022 Revolving Credit Facility. In addition, the Company repurchased and cancelled common shares totaling $13.2 million under the 2025 Share Repurchase Program and $1.7 million to satisfy employee income tax withholding obligations associated with the vesting of RSUs, while proceeds from the exercise of stock options were $1.4 million during the period.
Senior Credit Facilities
On November 29, 2022, the Company refinanced its existing borrowings under the prior Commercial Business Loan Agreement with Hancock Whitney Bank and entered into a new credit agreement (the "2022 Senior Credit Facilities") with the lenders from time to time party thereto, and Regions Bank, as administrative agent and collateral agent, that provides for an up to $30.0 million revolving credit facility (the "2022 Revolving Credit Facility") and an up to $30.0 million delayed draw term loan facility (the "2022 Term Loan Facility"), both maturing in November 2027. We expect to refinance or replace the facilities prior to maturity; however, there can be no assurance that replacement financing will be available on acceptable terms.
On May 28, 2024, the Company entered into a First Amendment to the 2022 Senior Credit Facilities that extended the delayed draw term loan commitment expiration date to November 29, 2025, from its initial expiration date of May 29, 2024, and provided for other technical amendments. On June 6, 2025, the Company entered into a Second Amendment to the 2022 Senior Credit Facilities that, among other things, increased the permitted amount of restricted payments that may be made by the Company and its subsidiaries, subject to specified conditions, and made other conforming and administrative changes. On November 7, 2025, the Company entered into a Third Amendment to the 2022 Senior Credit Facilities that, among other things, further extended the delayed draw term loan commitment expiration date from November 29, 2025 to November 29, 2026 and included other technical amendments.
The proceeds of the 2022 Revolving Credit Facility may be used to refinance existing indebtedness, for working capital purposes, capital expenditures and other general corporate purposes (including permitted acquisitions), and to pay transaction fees, costs and expenses related to the 2022 Senior Credit Facilities. The proceeds of the 2022 Term Loan Facility and any additional term loans established in accordance with the 2022 Senior Credit Facilities may be used to finance permitted acquisitions and to pay transaction fees, costs and expenses related to such acquisitions. Outstanding borrowings under the 2022 Term Loan Facility were $5.3 million as of September 30, 2026. There were no outstanding borrowings under the 2022 Revolving Credit Facility as of September 30, 2026.
The interest rates per annum applicable to the 2022 Senior Credit Facilities are Term SOFR plus an applicable margin, which ranges from 2.625% to 3.375%, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625% to 2.375%.
The 2022 Senior Credit Facilities require the Company to comply with certain affirmative, as well as certain negative covenants that, among other things, will restrict, subject to certain exceptions, the ability of the Company to incur indebtedness, grant liens, make investments, engage in acquisitions, mergers or consolidations and pay dividends and other restricted payments. The 2022 Senior Credit Facilities also include certain financial covenants, which generally include, but are not limited to the following:
•Consolidated Total Leverage Ratio (defined generally as total indebtedness to adjusted EBITDA) of not greater than (i) for any fiscal quarter ending during the period from the closing date to and including December 31, 2024, 2.75 to 1.0 and (ii)
Page 38 | ||||||||
for any fiscal quarter ending on and after March 31, 2025, 2.50 to 1.0, subject to certain adjustments following a material acquisition.
•Consolidated Fixed Charge Coverage Ratio (defined generally as (a) adjusted EBITDA minus capital expenditures minus cash taxes to (b) the sum of scheduled principal payments plus cash interest expense plus restricted payments) of not less than 1.25:1.0.
The Company was in compliance with all covenants under the 2022 Senior Credit Facilities in effect at September 30, 2026.
Use of Funds
Our principal uses of cash are funding the purchase of rental assets and other capital purchases, the repayment of debt, the repurchase of shares of our common stock, the funding of acquisitions, operations, and other working capital requirements. Our contractual obligations primarily relate to the repayment of existing debt and contractual obligations for operating leases. The following table presents our material contractual obligations and commitments to make future payments as of September 30, 2026:
| Within 12 Months | Beyond 12 Months | |||||||||||||
Debt Obligations, including interest | $ | 1,825 | $ | 4,797 | ||||||||||
Lease Obligations | 1,689 | 3,117 | ||||||||||||
| Total | $ | 3,514 | $ | 7,914 | ||||||||||
Except for the funding of potential acquisitions and investments, we anticipate that our operating cash flows will satisfy our material cash requirements for the 12 months after September 30, 2026. In addition to our operating cash flows, we may need to raise additional funds to support our contractual obligations and investing activities beyond such 12 month period, and such funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, our operations and ability to execute our business strategy could be adversely affected. We may seek to raise additional funds through equity, equity-linked or debt financings. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to holders of our equity securities and could contain covenants that restrict our operations. Any additional equity financing may be dilutive to our stockholders.
Leases
Leases under which we assume substantially all the risks and rewards of ownership are classified as finance leases. Upon initial recognition, the leased asset is measured at an amount equal to the lesser of its fair value and the present value of the minimum lease payments. Subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to the asset. The associated lease liability is drawn down over the life of the lease by allocating a portion of each lease payment to the liability with the remainder being recognized as finance charges. Leases that do not transfer the risks and rewards of ownership to the Company are treated as operating leases and are expensed as incurred.
Retirement Plan
The Company maintains a 401(k) retirement plan for employees to which eligible employees can contribute a percentage of their pre-tax compensation. Matching employer contributions to the 401(k) plan totaled $0.5 million for both the three months ended September 30, 2026 and 2025, and $1.6 million and $1.4 million for the nine months ended September 30, 2026 and 2025, respectively.
Off Balance Sheet Arrangements
The Company has no material undisclosed off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its results of operations or financial condition.
Page 39 | ||||||||
Accounting and Disclosure Matters
Critical Accounting Estimates
We are required to disclose “critical accounting estimates” which are estimates made in accordance with generally accepted accounting principles that involve a significant level of estimation uncertainty and that have had or are reasonably likely to have a material impact on our financial condition or results of operations.
We follow financial accounting and reporting policies that are in accordance with accounting principles generally accepted in the United States. The more significant of these policies are summarized in Note 2 to our consolidated financial statements included in Part II, Item 8 of the Company's Annual Report on Form 10-K for the year ended December 31, 2025. Not all significant accounting policies require management to make difficult, subjective or complex judgments. However, the policy noted below could be deemed to meet the SEC’s definition of a critical accounting estimate.
Accounts Receivable
Accounts receivable are recorded based upon contractually agreed-upon rates, reduced by estimated adjustments for variable consideration for implicit price concessions related to sales revenues and estimated probable losses related to rental revenues. Due to the nature of the industry and the reimbursement environment in which we operate, certain estimates are required in order to record revenues and accounts receivable net of these adjustments. Management’s evaluation takes into consideration such factors as historical realization data, including current and historical cash collections, accounts receivable aging trends, other operating trends and relevant business conditions.
Inherent in these estimates is the risk that they may have to be revised or updated as additional information becomes available. It is possible that management’s estimates could change, which could have an impact on operations and cash flows. Specifically, the complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. If the payment amount received differs from the estimated amount, an adjustment is made in the period that these payment differences are determined.
Recently Issued Accounting Pronouncements
See Note 2 – Summary of Significant Accounting Policies of our Condensed Consolidated Financial Statements for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial position and cash flows.
Page 40 | ||||||||
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our exposure to market risk primarily relates to fluctuations in interest rates from borrowings under the 2022 Senior Credit Facilities. The interest rates per annum applicable to the 2022 Senior Credit Facilities are Term SOFR plus an applicable margin, which ranges from 2.625% to 3.375%, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625% to 2.375%. Outstanding borrowings subject to interest rate fluctuations under the 2022 Term Loan Facility were $5.3 million as of September 30, 2026. There were no outstanding borrowings under the 2022 Revolving Credit Facility as of September 30, 2026. Based on our outstanding borrowings, an immediate 100 basis point change in interest rates would not have a material effect on our net income.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, the Company's management, including its Chief Executive Officer and Chief Financial Officer, completed an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 of the Exchange Act. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded:
i.that the Company's disclosure controls and procedures are designed to ensure (a) that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and (b) that such information is accumulated and communicated to the Company's management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure; and
ii.that the Company's disclosure controls and procedures are effective.
Notwithstanding the foregoing, there can be no assurance that the Company's disclosure controls and procedures will detect or uncover all failures of persons within the Company and its consolidated subsidiaries to disclose material information otherwise required to be set forth in the Company's periodic reports. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.
Changes in Internal Control Over Financial Reporting
There have been no changes in the Company's internal control over financial reporting during the three months ended September 30, 2026 that have materially affected, or that are reasonably likely to materially affect, the Company's internal control over financial reporting.
Page 41 | ||||||||
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may be subject to various ongoing or threatened legal actions and other proceedings, including those that arise in the ordinary course of business, which may include employment matters, breach of contract disputes, as well as governmental and regulatory matters. Please read Note 8—Commitments and Contingencies to our condensed consolidated financial statements included in Part I, Item 1, of this Quarterly Report on Form 10-Q for more information. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time.
Item 1A. Risk Factors
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 4, 2026, which could materially affect our business, financial condition or future results. There have been no material changes in our risk factors from those disclosed in that Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sales of Equity Securities
None.
Company Repurchases of Equity Securities
The following table sets forth certain information with respect to repurchases of our common shares during the three months ended September 30, 2026:
| Period | Total number of shares (or units) purchased (1) | Average price paid per share (2) | Total number of shares purchased as part of publicly announced plans or programs (3) | Maximum number of shares that may yet be purchased under the plans or programs | ||||||||||||||||||||||
Jul 1- Jul 31, 2026 | — | $— | — | 1,249,329 | ||||||||||||||||||||||
Aug 1- Aug 31, 2026 | 14,930 | $8.92 | 10,000 | 1,239,329 | ||||||||||||||||||||||
Sep 1- Sep 30, 2026 | 105,000 | $8.90 | 105,000 | 1,134,329 | ||||||||||||||||||||||
| Total | 119,930 | $8.90 | 115,000 | 1,134,329 | ||||||||||||||||||||||
(1)This amount includes 4,930 common shares acquired at a cost of $44,000 to satisfy employee income tax withholding associated with RSUs vesting.
(2)Average price paid per share includes broker commissions but excludes taxes payable.
(3)On March 4, 2026, the Company's Board of Directors authorized and approved the 2026 Share Repurchase Program. Under the terms of the 2026 Share Repurchase Program, the Company may repurchase up to 1,930,131 of its common shares from time to time through open market purchases, block purchases or otherwise in accordance with applicable securities laws, including Rule 10b-18 of the Exchange Act. The 2026 Share Repurchase Program is set to expire in March 2027, unless earlier suspended or terminated.
Dividends
We have not declared or paid any cash or stock dividends on our common shares since our inception. Any future determination as to the declaration and payment of cash dividends will be at the discretion of the Board and will depend on then-existing conditions, including our financial condition, results of operations, contractual restrictions, capital requirements, business prospects, and other factors that the Board considers relevant. Our subsidiaries are restricted from making distributions or dividend payments to us by the 2022 Senior Credit Facilities (as defined above), subject to certain exceptions. See Note 5 to the Financial Statements, included in Part I, Item 1, of this Quarterly Report on Form 10-Q for further information.
Page 42 | ||||||||
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements
On September 24, 2026 , Moore Faster LLC, an entity controlled by Michael Moore , the Company’s President , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. The plan provides for the potential sale of up to 246,000 of the Company’s common shares beneficially owned by Mr. Moore. Sales under the plan may commence no earlier than December 24, 2026, and the plan is scheduled to terminate on November 30, 2027 , subject to earlier termination in accordance with its terms.
Except as described above, during the fiscal quarter ended September 30, 2026, no director or officer (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) of the Company adopted or terminated
Page 43 | ||||||||
Item 6. Exhibits
The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.
| Exhibit Number | Exhibit Title | |||||||
| #2.1 | ||||||||
| 3.1 | ||||||||
| 3.2 | ||||||||
| *31.1 | ||||||||
| *31.2 | ||||||||
| **32.1 | ||||||||
| **32.2 | ||||||||
| *101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||||
| *101.SCH | Inline XBRL Taxonomy Extension Schema Document. | |||||||
| *101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
| *101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||
| *101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
| *101.DEF | Inline XBRL Taxonomy Extension Definition Document. | |||||||
| *104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | |||||||
| * Filed herewith. | ||||||||
| ** Furnished in accordance with Item 601(b)(32)(ii) of Regulation S-K. | ||||||||
# Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request. | ||||||||
Page 44 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
VIEMED HEALTHCARE, INC. | ||||||||
| (Registrant) | ||||||||
| By: | /s/ Casey Hoyt | |||||||
| Casey Hoyt | ||||||||
| Chief Executive Officer | ||||||||
| By: | /s/ Trae Fitzgerald | |||||||
| Trae Fitzgerald | ||||||||
| Chief Financial Officer | ||||||||
Date: November 4, 2026
Page 45 | ||||||||
Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Casey Hoyt, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 4, 2026
/s/ Casey Hoyt | |||||
Casey Hoyt Chief Executive Officer | |||||
Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Trae Fitzgerald, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 4, 2026
/s/ Trae Fitzgerald | |||||
Trae Fitzgerald Chief Financial Officer | |||||
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Casey Hoyt, the Chief Executive Officer of Viemed Healthcare, Inc. (the “Company”), hereby certify, that, to my knowledge:
1.The Quarterly Report on Form 10-Q for the period ended September 30, 2026 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 4, 2026
/s/ Casey Hoyt | |||||
Casey Hoyt Chief Executive Officer | |||||
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Trae Fitzgerald, the Chief Financial Officer of Viemed Healthcare, Inc. (the “Company”), hereby certify, that, to my knowledge:
1.The Quarterly Report on Form 10-Q for the period ended September 30, 2026 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 4, 2026
/s/ Trae Fitzgerald | |||||
Trae Fitzgerald Chief Financial Officer | |||||